What Happened?
South San Fransico, CA-based Tizona Therapeutics Appointed Scott Clarke as Chief Executive Officer
About the Company
Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies. Tizona Therapeutics, Inc. was founded by MPM Capital and leading scientists from Dana Farber Cancer Institute, the University of Pittsburgh, Johns Hopkins, Memorial Sloan Kettering Cancer Center, and Brigham and Women`s Hospital.
About the Person
Pablo Cagnoni, M.D., joined MPM in 2015. Pablo is the CEO of MPM portfolio company Tizona Therapeutics and Executive chair of Blade Therapeutics. Over of the course of his career as an oncologist and pharmaceutical executive, Pablo has been committed to advancing the development of breakthrough treatments for patients with cancer and other debilitating diseases. He has played a key role in the development, approval and/or commercialization of several life-changing medicines, including Afinitor®, Blincyto® Exjade®, Folotyn® Glivec®, Jakavi®, Kyprolis®, Signifor®, Tarceva®, Tasigna® and Zykadia® among them. Most recently, he served as President of Onyx Pharmaceuticals where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. At the time of his departure, Onyx was on track to deliver yearly revenues in excess of $1B and had over 800 employees. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen (AMGN) subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology (NVS), where he was responsible for all clinical development, clinical operations, clinical pharmacology and correlative sciences activities for the oncology development pipeline. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals: SPPI) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas:TSE 1st 4503). Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program where he cared for patients undergoing stem cell transplants. Pablo earned his medical degree from University Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology in Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
Info Source
Press Release
Short Profile